Please assess the completion status of the following clinical trial:

Trial Title: Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diarrhea, defined as greater than 4 bowel movements per day and greater than mild; currently on no treatment or active despite treatment.~* Lymphocytic colitis confirmed histologically within one year of enrollment~Exclusion Criteria:~* Previous unsuccessful treatment with corticosteroids or immunosuppressive drugs~* History of severe corticosteroid side effects~* Corticosteroid, ticlopidine, or flutamide use within the previous 4 weeks~* Antibiotic, mesalamine or bismuth subsalicylate use within two weeks~* Current use of anticholinergics, cholestyramine, narcotics, ketoconazole, itraconazole, ritonavir, indinavir, saquinavir, erythromycin, or grapefruit juice~* Known active medical conditions, including cancer, infection, uncontrolled hypertension or diabetes, osteoporosis, peptic ulcer disease, glaucoma, cataracts, liver cirrhosis or history of tuberculosis~* Other diarrheal conditions (sprue, infection, hyperthyroidism, lactose intolerance)~* Pregnant or nursing females~* Patients without a telephone or unable to communicate in English over the telephone, or unable or unwilling to give consent~* Known hypersensitivity to or intolerance of budesonide.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Budesonide (Type: ACTIVE_COMPARATOR): 9 mg daily
- Placebo (Type: PLACEBO_COMPARATOR): three tablets daily

Based on this trial design, predict the completion outcome and termination type (if applicable).